CD274 and neoplasm: Considering the predictive biomarkers, phase II and III trails have indicated that PD-L1 expression evaluated as a combined positive score (CPS) in both tumor cells and immune cells is associated with efficacy—a higher CPS is correlated with greater treatment effect [17].